|
A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors. |
|
|
Consulting or Advisory Role - Rafael Pharmaceuticals |
Speakers' Bureau - Bristol-Myers Squibb; Merck |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Rafael Pharmaceuticals |
|
|
Honoraria - ABL bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; Roche/Genentech |
Consulting or Advisory Role - ABL Bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; Roche |
Research Funding - Astex Pharmaceuticals; AstraZeneca; Merck |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EMD Serono |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Eisai; Exelixis; Genentech |
Research Funding - Merck KGaA; Oncolytics |
|
|
Research Funding - Seagen (Inst) |
|
|
|
|
|
|
|
|
|
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|